Genital Herpes Therapeutic Pipeline Analysis | Insights into the ... - Digital Journal

PRESS RELEASE

Published April 25, 2023

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Genital Herpes pipeline constitutes 26+ key companies continuously working towards developing 28+ Genital Herpes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Genital Herpes Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Genital Herpes Market.

The Genital Herpes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Genital Herpes Pipeline Report:
• Companies across the globe are diligently working toward developing novel Genital Herpes treatment therapies with a considerable amount of success over the years.
• Genital Herpes companies working in the treatment market are Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutic, AiCuri, and others, are developing therapies for the Genital Herpes treatment
• Emerging Genital Herpes therapies such as – mRNA 1608, Attenuated vaccine against HSV 1&2, HSV "Genital lesions" Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, Pritelivir, and others are expected to have a significant impact on the Genital Herpes market in the coming years.
• In May 2021, X-Vax Technology announced that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental vaccine against herpes simplex virus 1 and 2 (HSV-1 and -2).
• In July 2020, AiCuris Anti-infective Cures AG initiated a single-center, open-label, 2-periodfixed-sequence Phase I trial to evaluate the potential influence of Pantoprazole on the pharmacokinetics of Pritelivir

Genital Herpes Overview
Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1.

Get a Free Sample PDF Report to know more about Genital Herpes Pipeline Therapeutic Assessment

Emerging Genital Herpes Drugs Under Different Phases of Clinical Development Include:
• mRNA 1608: Moderna Therapeutics
• Pritelivir: AiCuris
• Attenuated vaccine against HSV 1&2: Vaxxit
• HSV "Genital lesions" Skin cream/Lotion: Nanoviricides
• BNT 163: BioNTech
• GSK 3943104A: GlaxoSmithKline
• UB 621: United BioPharma
• HDIT101: Heidelberg ImmunoTherapeutic
• Pritelivir: AiCuri

Route of Administration
Genital Herpes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Genital Herpes Pipeline Therapeutics Assessment
• Genital Herpes Assessment by Product Type
• Genital Herpes By Stage and Product Type
• Genital Herpes Assessment by Route of Administration
• Genital Herpes By Stage and Route of Administration
• Genital Herpes Assessment by Molecule Type
• Genital Herpes by Stage and Molecule Type

DelveInsight's Genital Herpes Report covers around 28+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Genital Herpes product details are provided in the report. Download the Genital Herpes pipeline report to learn more about the emerging Genital Herpes therapies

Some of the key companies in the Genital Herpes Therapeutics Market include:
Key companies developing therapies for Genital Herpes are – Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg, ImmunoTherapeutics, AiCuris, United Biopharma, and others.

Genital Herpes Pipeline Analysis:
The Genital Herpes pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Genital Herpes with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Genital Herpes Treatment.
• Genital Herpes key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Genital Herpes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Genital Herpes market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Genital Herpes drugs and therapies

Genital Herpes Pipeline Market Drivers
• Increasing awareness among the population regarding genital herpes infection, availability of high sensitivity and specificity of nucleic acid amplification based kits test type are some of the important factors that are fueling the Genital Herpes Market.

Genital Herpes Pipeline Market Barriers
• However, accessibility of diagnostic services, Insufficient R&D initiatives, pricing pressures, and stringent regulations, lack of novel strategies to prevent or suppress HSV-2 infection and other factors are creating obstacles in the Genital Herpes Market growth.

Scope of Genital Herpes Pipeline Drug Insight
• Coverage: Global
• Key Genital Herpes Companies: Moderna Therapeutics, Vaxxit, Nanoviricides, BioNTech, GlaxoSmithKline, United BioPharma, Heidelberg ImmunoTherapeutic, AiCuri, and others
• Key Genital Herpes Therapies: mRNA 1608, Attenuated vaccine against HSV 1&2, HSV "Genital lesions" Skin cream/Lotion, BNT 163, GSK 3943104A, UB 621, HDIT101, Pritelivir, and others
• Genital Herpes Therapeutic Assessment: Genital Herpes current marketed and Genital Herpes emerging therapies
• Genital Herpes Market Dynamics: Genital Herpes market drivers and Genital Herpes market barriers

Request for Sample PDF Report for Genital Herpes Pipeline Assessment and clinical trials

Table of Contents
1 Genital Herpes Report Introduction
2 Genital Herpes Executive Summary
3 Genital Herpes Overview
4 Genital Herpes- Analytical Perspective In-depth Commercial Assessment
5 Genital Herpes Pipeline Therapeutics
6 Genital Herpes Late Stage Products (Phase II/III)
7 Genital Herpes Mid Stage Products (Phase II)
8 Genital Herpes Early Stage Products (Phase I)
9 Genital Herpes Preclinical Stage Products
10 Genital Herpes Therapeutics Assessment
11 Genital Herpes Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Genital Herpes Key Companies
14 Genital Herpes Key Products
15 Genital Herpes Unmet Needs
16 Genital Herpes Market Drivers and Barriers
17 Genital Herpes Future Perspectives and Conclusion
18 Genital Herpes Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports by DelveInsight- 

scedosporium infection market | autoimmune pulmonary alveolar proteinosis market | rosai-dorfman disease market | sandhoff disease market | b-cell chronic lymphocytic leukemia market | bladder cancer market | trichomoniasis market | bile duct cancer market | resorbable vascular scaffold market | salivary gland infection market | ischemic stroke market | paget's disease market | ventricular assist devices market | vascular stents market | vascular graft devices market | bladder scanners market | b-cell non-hodgkin lymphoma market | basal cell carcinoma market | birch allergy market | vein illumination devices market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:
Gaurav Bora
[email protected]
+1(919)321-6187
Healthcare Consulting

Newsmantraa

Comments

Post a Comment

Popular posts from this blog

Effect of a board game on imprisoned women's knowledge about ... - BMC Public Health

Image
The Previna board game was designed to be a complementary tool in the teaching and learning process about STIs for imprisoned women. The results showed that this educational technology significantly increased the players' knowledge about STIs and that this increase in knowledge remained significant during follow-up. This suggests that there was knowledge retention in the period researched. The increase in knowledge was also present in other studies that used board games for educational purposes [13,14,15,16]. The knowledge retention observed in this study is a result that draws attention, as the school teachers frequently mentioned that the women had difficulty retaining the contents taught in the classroom. This suggests that the approach to content may or may not favor this process. In this way, the board game can be used to present educational content to adult students in order to address their learning needs [14] and to make learning more significant and engaging. Regardless of...
Read more

Herpes Simplex: Two Types, Comparison Chart, Prevention - Verywell Health

Image
Herpes is a viral infection transmitted through skin contact. The two most common strains, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), cause oral herpes (cold sores) and genital herpes infections. Between 50% and 80% of people in the United States have HSV-1, and almost 12% of people between the ages of 14 and 49 have an HSV-2 infection. Read on for more information on both herpes simplex viruses, including transmission, symptoms, diagnosis, and treatment. belchonock / Getty Images Types of Herpes Simplex There are two types of HSV strains: HSV-1 : This strain typically causes an oral herpes infection but can cause symptoms in the genital area if that is where the virus was transmitted. HSV-2 : This virus strain typically causes symptoms in the genital and anal area. It may also cause an infection in or around the mouth. While each strain does commonly cause an infection on a particular part of the body, it is possible fo...
Read more

The 5 Best OTC Cold Sore Treatments of 2024 - Health.com

Image
Cold sores are quite common, and many people have a cold sore outbreak a few times a year. Itchy, painful, irritated, and sensitive cold sores are caused by the herpes simplex virus type 1 (HSV-1) and, less commonly, HSV 2. According to the World Health Organization, an estimated 3.7 billion people globally have an HSV-1 infection at a given time, which is the main cause of cold sores. Most cold sores go away within a few weeks without treatment. However, multiple over-the-counter (OTC) ways to treat cold sores can help speed healing without needing to see a healthcare provider. Many people use oral treatments for prevention or treatment, explains Allison K. Truong, MD, a board-certified dermatologist in Beverly Hills, CA. These can reduce symptoms to seven days or prevent the cold sore from forming if you catch it early enough. We surveyed 28 participants to find out which OTC cold sore treatment they tried, how effective it was, and why they liked it. The below over-the-c...
Read more